Aigerim Aldiyarovna Balapasheva

Dr. Aigerim Aldiyarovna Balapasheva

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
NANurgul Ablakimova
Nurgul Ablakimova
AMAigul Z. Mussina
Aigul Z. Mussina
GSGaziza A. Smagulova
Gaziza A. Smagulova
Svetlana RachinaSvetlana Rachina
Svetlana Rachina
MKMeirambek S. Kurmangazin
Meirambek S. Kurmangazin
FRFarhad Rahmanifar
Farhad Rahmanifar
This cross-sectional study investigated the microbial landscape and antibiotic-resistance patterns in patients with bacterial pneumonia, with a focus on the impact of COVID-19. Sputum samples from individuals with bacterial pneumonia, including coronavirus disease 2019-positive polymerase chain reaction (COVID-19-PCR+), COVID-19-PCR− and non-COVID-19 patients, were analyzed. Surprisingly, the classic etiological factor of bacterial pneumonia, Streptococcus pneumoniae, was rarely isolated from the sputum samples. Furthermore, the frequency of multidrug-resistant pathogens was found to be higher in non-COVID-19 patients, highlighting the potential impact of the pandemic on antimicrobial resistance. Strains obtained from COVID-19-PCR+ patients exhibited significant resistance to commonly used antibiotics, including fluoroquinolones and cephalosporins. Notably, the ESKAPE pathogens, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae, and Enterobacter aerogenes, were identified among the isolated microorganisms. Our findings underscore the urgent need for infection control measures and responsible antibiotic use in healthcare settings, as well as the importance of enhancing pneumonia diagnostics and implementing standardized laboratory protocols.

6 November 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
ABAigerim Aldiyarovna Balapasheva
Aigerim Aldiyarovna Balapasheva
GSGaziza A. Smagulova
Gaziza A. Smagulova
AMAigul Z. Mussina
Aigul Z. Mussina
Liliya Eugenevna ZiganshinaLiliya Eugenevna Ziganshina
Liliya Eugenevna Ziganshina
ZNZhansulu Zh. Nurgaliyeva
Zhansulu Zh. Nurgaliyeva
In the context of the global spread of Coronavirus Disease 2019 (COVID-19), the issue of evaluating and optimizing the use of antibacterial drugs becomes especially relevant. The coronavirus pandemic has provided a unique opportunity to study the dynamics of the consumption of antibacterial agents and their impact on public health. The rational use of antibiotics is a key aspect of the fight against antimicrobial resistance, which makes this study particularly important. The aim of this study was to assess changes in the consumption of antibacterial drugs among patients hospitalized with COVID-19 during the peak of the 2020 pandemic and compare them with data from 2019 prior to the pandemic. This study collated data on antibacterial drug consumption in a regional hospital in Aktobe, which served a large population of patients during the pandemic. A pharmacoepidemiological study was conducted using the Anatomical Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) methodology. The pharmacoepidemiological study using the international ATC/DDD methodology revealed a concerning pattern of irrational consumption of antibacterial drugs, including cephalosporins, azalides, second-generation fluoroquinolones, and systemic aminoglycosides in Aktobe. Among antibacterial drugs during the pandemic, the most significant increase in consumption was from the group of cephalosporins (19,043 DDD/100 bed-days). The share of their consumption was 35.4% of the total consumption of antibacterial drugs. Pharmacoepidemiological studies using the international methodology ATC/DDD showed an alarming picture of irrational consumption of antibacterial drugs of the group of cephalosporins, azalides, fluoroquinolones, and aminoglycosides in Aktobe, and, in this case, excessive use of the identified antibiotics raises concerns about the possibility of increasing the problem of resistance to microbes.

1 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ABAigerim Aldiyarovna Balapasheva
Aigerim Aldiyarovna Balapasheva
GSGaziza A. Smagulova
Gaziza A. Smagulova
AMAigul Z. Mussina
Aigul Z. Mussina
DDDaniyar S. Dilmagambetov
Daniyar S. Dilmagambetov
KYKalzhan Zh. Yermekbayeva
Kalzhan Zh. Yermekbayeva
LZLiliya E. Ziganshina
Liliya E. Ziganshina
Antimicrobial resistance is a major global challenge, and the World Health Organization (WHO) promotes the Access, Watch, and Reserve (AWaRe) classification to support rational antibiotic use. In Kazakhstan, irrational prescribing remains common, and the COVID-19 pandemic intensified the misuse of broad-spectrum antibiotics. A retrospective study at a hospital in Aktobe (2019–2021) analyzed antibiotic use from pharmacy and medical records using the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) methodology, with categorization by the WHO AWaRe classification. The analysis revealed a persistent predominance of “Watch” antibiotics, particularly cephalosporins, fluoroquinolones, and carbapenems, with their use intensifying during the COVID-19 pandemic. The share of “Access” antibiotics remained well below the WHO-recommended target of 60%, fluctuating between 24% and 27% across the study period. Reserve antibiotics were not prescribed. The findings reveal gaps in antibiotic stewardship in Kazakhstan: overreliance on “Watch” antibiotics and underuse of “Access” drugs, contrary to WHO guidance. Implementing the AWaRe framework with national targets and monitoring is essential, and the study adds regional evidence to the global AMR discourse, underscoring the need for stronger policies, especially during pandemics.

23 April 2024 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
ABAigerim Aldiyarovna Balapasheva
Aigerim Aldiyarovna Balapasheva
AMAigul Zakarievna Mussina
Aigul Zakarievna Mussina
GSGaziza Azhmagievna Smagulova
Gaziza Azhmagievna Smagulova
Liliya Eugenevna ZiganshinaLiliya Eugenevna Ziganshina
Liliya Eugenevna Ziganshina
Aim: The study aimed to analyze the frequency and structure of antibacterial drug consumption during the COVID-19 pandemic at a dispensary hospital in Aktobe, Kazakhstan. It sought to identify the most frequently used and most costly antibacterial drugs, assessing their economic impact and usage patterns. Methods: This descriptive, retrospective clinical, economic, and pharmacoepidemiological study was conducted using data from the dispensary hospital's pharmacy and patient records between March 13, 2020, and December 31, 2020. The ABC/VEN analysis and ATC/DDD methodology were applied to evaluate the consumption of antibacterial drugs. Antibiotics were classified according to WHO AWARe criteria. Results: The study found that 27 different antibacterial drugs were used, representing 2.2% of all medications. The ABC/VEN analysis revealed that the majority of the budget was spent on a few high-cost drugs. Ceftriaxone was the most commonly used antibiotic, with a significant financial impact. According to the WHO AWaRe classification, most antibiotics fell into the Access and Watch categories. Conclusion: The study highlights a high rate of antibacterial drug usage, with significant financial implications for the hospital. The predominance of certain high-cost antibiotics, like ceftriaxone, indicates a need for more rational and cost-effective use of these medications. The findings call for improved adherence to clinical guidelines, enhanced education for medical professionals, and optimized antibiotic utilization to prevent resistance development and ensure better patient outcomes, especially in pandemic situations.

27 February 2026 in Medicine
Verified
Journal Article
Open access
LBLazzat Balymbetova
Lazzat Balymbetova
YIYerbolat Maratovich Iztleuov
Yerbolat Maratovich Iztleuov
EIElnara Kereevna Ismagulova
Elnara Kereevna Ismagulova
SKSarkyt Kozhantayeva
Sarkyt Kozhantayeva
ABAigerim Aldiyarovna Balapasheva
Aigerim Aldiyarovna Balapasheva
Background: Lung cancer incidence is increasing worldwide. Despite being cornerstone treatment modalities, both chemotherapy and targeted therapy are accompanied by treatment-related toxicities. The aim of this study is to identify key authors, leading countries, core journals, and keywords in research on treatment-related toxicities of tyrosine kinase inhibitors (TKIs) used for non-small-cell lung cancer (NSCLC). Methods: A literature search was conducted in the Web of Science Core Collection database on June 28, 2025. The search strategy used the terms “non-small cell lung cancer,” “toxicity,” and “tyrosine kinase inhibitors,” and their combination with Boolean operators (AND, OR, NOT). Bibliometric analyzes were conducted using the Bibliometrix R-package along with the Biblioshiny interface for visualization and data exploration. Results: A total of 366 publications on TKIs in NSCLC were identified between 2009 and 2025. Annual scientific production increased from 2 to 56 publications, with an average annual growth rate of 20%. China led with 580 papers, followed by Japan (381) and the United States (358). Harvard University ranked first among institutions (n = 46), followed by its medical affiliates, Pfizer, and the University of California System. The most productive journal was Lung Cancer (n = 18), whereas the Journal of Clinical Oncology had the highest impact factor (IF = 41.9). The most cited publication was Peters et al, which received 1830 citations, while average citation per article is 23. Analysis of author keywords revealed 3 major thematic clusters, encompassing strategies to overcome resistance, approaches to manage TKI-related toxicities, and studies on specific molecular subtypes (anaplastic lymphoma kinase, epidermal growth factor receptor). The most prevalent keywords were “non-small cell lung cancer” (32%) and “osimertinib” (23%), reflecting the central focus on third-generation TKIs in current research. Conclusions: Optimizing NSCLC therapy with TKIs requires proactive toxicity monitoring and integration of predictive biomarkers and real-world evidence to enhance efficacy and patient safety.